NEW MJ NEWS

TILT Holdings Reports Fourth Quarter and Full-Year 2020 Financial Results Including First Full-Year of Positive Adjusted EBITDA

TILT Holdings Inc. (“TILT” or the “Company”) (CSE: TILT) (OTCQB: TLLTF) a provider of business solutions to the global cannabis industry that includes inhalation technologies, cultivation, manufacturing, processing, brand development and retail, reported its financial and operating results for the three and twelve-months ended December 31, 2020. All financial information is provided in U.S. dollars except where otherwise indicated. Results of Yaris Acquisition, LLC and its subsidiaries (together, “Blackbird”) have been reclassified as discontinued operations on the income statement and statement of cash flows. All periods have been updated to reflect this change.

“The primary focus in 2020 was for TILT to become profitable, putting in place the pieces necessary to achieve scale and engage in a steady and sustainable growth trajectory,” said Gary Santo, President of TILT. “We made a number of key decisions throughout the year that have already started to pay off, allowing the Company to have a strong finish to 2020, producing $16.9 million in Adjusted EBITDA and $16.7 million in cash from operating activities for the year. We look to carry that momentum into 2021 and are already off to a great start across all business units, supporting management’s previously announced full-year 2021 revenue guidance of $205 million to $210 million and Adjusted EBITDA guidance of $30 million to $32 million.”

“TILT underwent significant changes in 2020,” added Mark Scatterday, CEO of TILT. “Through the tireless efforts of our team we were able to stabilize our foundation, solidify our strategy and focus on how best to deploy available resources towards our high-growth plant touching assets, allowing TILT to provide a differentiated B2B platform capable of supporting independent brands, U.S. MSOs and Canadian LPs. We expect 2021 to be an exciting year as we continue our transition from being a holding company possessing a disparate collection of subsidiaries to an integrated operating company capable of benefitting from economies of scale and cross-selling opportunities.”

Financial Highlights from Continuing Operations for the Quarter Ended December 31, 2020

Revenue of $42.3 million, an 8.1% increase from the third quarter of 2020 and an increase of 35.4% from the prior year period.

Gross margin before fair value adjustments of 26.7%, down 460 basis points (“bps”) from the third quarter of 2020 and up 200 bps from the prior year period.

Operating expenses less non-cash adjustments for stock compensation, depreciation/ amortization and one-time charges was $8.3 million, flat compared to the third quarter and a 17.7% decline from the prior year period.

Positive Adjusted EBITDA for the fourth consecutive quarter at $4.5 million.

Cash and cash equivalents of $7.4 million, a $3.1 million increase from the previous quarter, due to robust cashflow from operations.

Working Capital of $57.4 million, an $8.5 million increase from the previous quarter.

Operational Highlights for the Quarter Ended December 31, 2020

Jupiter Research LLC’s (“Jupiter”) power supply revenue doubled from Q3 2020 to Q4 2020.

Standard Farms, LLC (“Standard Farms”) posted record revenue for the quarter, including the two highest sales months in Company history.

Standard Farms doubled extraction processing capacity during the quarter.

Commonwealth Alternative Care, Inc.’s (“CAC”) lab and kitchen production capacity increased 100% during the quarter; cultivation expansion approved October 2020 planted during Q4 2020 and yielded first harvest in March 2021.

Completed sale of Blackbird.

Operational Highlights Subsequent to Quarter End

Closed acquisition of Standard Farms Ohio LLC.

Jupiter saw record cartridge shipments in January and record orders in February.

Jupiter received ISO 13485:2016 Medical Device Certification.

Launch of Her Highness NYC branded products in Massachusetts within 30 days of signing manufacturing and distribution contract.

CAC completed planting in its eight additional grow rooms in Massachusetts during the quarter.

Standard Farms had its highest flower sales during the month of March.

Earnings Call and Webcast

The Company will host a webcast at 8:00 AM EDT to discuss financial and operational results for the reported quarter.

The live webcast may be accessed from the Events and Presentations menu in the Investor Relations section of the Company’s website at https://investors.tiltholdings.com/ir-calendar or to access the conference call via telephone, please dial, 1-877-705-6003. Please register at least 15 minutes prior to the scheduled start to download and install any necessary audio software.

A replay of the webcast will be available in the Past Events section of the Company’s Investor Relations website approximately 2 hours after the live event and will be archived for 30 days.

About TILT

TILT helps cannabis businesses build brands. Through a portfolio of companies providing technology, hardware, cultivation and production, TILT services brands and cannabis retailers across 35 states in the U.S., as well as Canada, Israel, Mexico, South America and the European Union. TILT’s core businesses include Jupiter, a wholly owned subsidiary and leader in the vaporization segment focused on hardware design, research, development and manufacturing; and cannabis operations, CAC in Massachusetts, Standard Farms in Pennsylvania and Standard Farms Ohio, LLC. TILT is headquartered in Phoenix, Arizona. For more information, visit www.tiltholdings.com.

Forward-Looking Information

This news release contains forward-looking information based on current expectations. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward looking information may include, without limitation, expectations regarding 2021 revenue and Adjusted EBITDA guidance, the anticipated transition from a holding company to an integrated operating company capable of benefitting from economies of scale and cross-selling opportunities, the opinions or beliefs of management, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of TILT, and includes statements about, among other things, future developments, the future operations, strengths and strategy of TILT. Generally, forward looking information can be identified by the use of forward looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These statements should not be read as guarantees of future performance or results. These statements are based upon certain material factors, assumptions and analyses that were applied in drawing a conclusion or making a forecast or projection, including TILT’s experience and perceptions of historical trends, the ability of TILT to maximize shareholder value, current conditions and expected future developments, as well as other factors that are believed to be reasonable in the circumstances.

Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that it will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. TILT assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

By its nature, forward-looking information is subject to risks and uncertainties, and there are a variety of material factors, many of which are beyond the control of TILT, and that may cause actual outcomes to differ materially from those discussed in the forward-looking statements.

For additional information regarding forward-looking statements and their related risks, please refer to the “Risk Factors and Uncertainties” section in the Management Discussion and Analysis of the Company for the quarter and year ended on December 31, 2020, which is available on the Company’s SEDAR profile at www.sedar.com.

Non-IFRS Financial and Performance Measures

In addition to providing financial measurements based on International Financial Reporting Standards (“IFRS”), the Company provides additional financial metrics that are not prepared in accordance with IFRS. Management uses non-IFRS financial measures, in addition to IFRS financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate the Company’s financial performance. These non-IFRS financial measures are EBITDA and Adjusted EBITDA.

Management believes that these non-IFRS financial measures reflect the Company’s ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as they facilitate comparing financial results across accounting periods and to those of peer companies. Management also believes that these non-IFRS financial measures enable investors to evaluate the Company’s operating results and future prospects in the same manner as management. These non-IFRS financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company’s ongoing operating results.

As there are no standardized methods of calculating these non-IFRS measures, the Company’s methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others.

Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.

EBITDA and Adjusted EBITDA

EBITDA and Adjusted EBITDA are financial measures that are not defined under IFRS. The Company uses these non-IFRS financial measures, and believes they enhance an investor’s understanding of the Company’s financial and operating performance from period to period, because they exclude certain material non-cash items and certain other adjustments management believes are not reflective of the Company’s ongoing operations and performance. The Company calculates EBITDA as net income (loss), plus (minus) income taxes (recovery), plus (minus) finance expense (income), plus depreciation and amortization expense. Adjusted EBITDA excludes certain one-time, non-cash or non-operating expenses, as determined by management, including stock compensation expense, business acquisition expense, debt issuance costs, severance, unrealized (gain) loss on changes in fair value of biological assets and fair value changes in biological assets included in inventory sold.

Reconciliations of Non-IFRS Financial and Performance Measures
Adjusted EBITDA is reconciled to Net Loss below as well as the section labelled “Reconciliation of Net Income (Loss) to Non-IFRS Measures” in the Management Discussion and Analysis of the Company for the quarter and year ended on December 31, 2020, which is available on the Company’s SEDAR profile at www.sedar.com.

Selected Financial Results

Table 1: Income Statement:
(in US$ thousands, unaudited)

Three Months Ended

Year Ended

($ thousands)

Dec 31, 2020

Sep 30, 2020

Dec 31, 2019

Dec 31, 2020

Dec 31, 2019

Dec 31, 2018

Revenue

$

42,265

$

39,083

$

31,225

$

158,409

$

146,935

$

3,502

Cost of Goods Sold

30,985

26,846

23,517

111,738

106,236

3,360

Gross Profit, Before FV Adj.

11,280

12,237

7,708

46,671

40,699

142

Gross Margin %, Before FV Adj.

26.7%

31.3%

24.7%

29.5%

27.7%

4.1%

Gain on FV of Bio. Assets

13,650

14,477

9,250

47,298

37,459

151

FV of Bio. Assets in Inventory Sold

-14,063

-7,870

-5,348

-35,014

-19,790

Gross Profit, After FV Adj.

10,867

18,844

11,610

58,955

58,368

293

Gross Margin %, After FV Adj.

25.7%

48.2%

37.2%

37.2%

39.7%

8.4%

Total Operating Expenses

49,703

14,453

38,613

93,552

170,354

56,582

Income (Loss) from Continuing Operations

-38,836

4,391

-27,003

-34,597

-111,985

(56,289)

Total Other Income (Expense)

-15,841

-2,476

-9,200

-22,552

-13,217

(493,782)

Income Tax Expense (Recovery)

-9,313

3,639

-4,582

-5,043

-3,275

48

Net (Loss) from Continuing Operations

-45,364

-1,724

-31,621

-52,107

-121,927

(550,119)

Net (Loss) from discontinued operations, net of tax

-46,783

-2,893

-1,050

-53,650

-11,447

Net (Loss)

$

(92,147)

$

(4,617)

$

(32,671)

$

(105,757)

$

(133,374)

$

(550,119)

EBITDA, Non-IFRS

-49,612

9,673

-27,881

-29,032

-89,022

(551,621)

Adjusted EBITDA, Non-IFRS

$

4,545

$

5,063

$

1,564

$

16,924

$

(845)

$

(22,634)

Table 2: Reconciliation of Non-IFRS Measures:
(in US$ thousands, unaudited)

Three Months Ended

Year Ended

($ thousands)

Dec 31, 2020

Sep 30, 2020

Dec 31, 2019

Dec 31, 2020

Dec 31, 2019

Dec 31, 2018

Net (Loss) from Continuing Operations

$

(45,364)

$

(1,724)

$

(31,621)

$

(52,107)

$

(121,927)

$

(550,119)

Add (Deduct) Impact of:

Interest (Income)

(1,595)

(767)

(843)

(3,835)

(3,280)

(2,199)

Finance Expense

1,847

2,981

4,398

10,336

13,463

Income Tax Expense (Recovery)

(9,313)

3,639

(4,582)

(5,043)

(3,275)

48

Depreciation and Amortization

4,813

5,544

4,767

21,617

25,997

649

Total Adjustments

(4,248)

11,397

3,740

23,075

32,905

(1,502)

EBITDA (Non-IFRS)

$

(49,612)

$

9,673

$

(27,881)

$

(29,032)

$

(89,022)

$

(551,621)

Add (Deduct) Impact of:

Stock Compensation Expense

817

1,456

2,914

4,200

75,628

28,967

Business Acquisition Expense

1,020

2,440

4,047

Debt Issuance Costs

540

209

Severance

1,026

279

1,204

Foreign Exchange (Gain) Loss

(76)

107

(Gain) Loss on Sale of Assets

(32)

102

598

70

610

Lease Restructuring Costs

280

Legal Settlement

275

275

Unrealized (Gain) Loss on Investment in Equity Security

23

301

337

Loss on Loan Receivable

16,416

4,689

16,416

4,689

One time bad debt expense

2,169

2,169

Impairment (Recovery) of Inventory

(1,418)

1,418

Derecognition and impairment loss

34,076

138

22,560

34,214

22,560

494,448

Unrealized (Gain) on Changes in FV of Bio. Assets

(13,650)

(14,477)

(9,250)

(47,298)

(37,459)

FV Changes in Bio. Assets Included in Inventory Sold

14,063

7,870

5,348

35,014

19,790

Total Adjustments

54,157

(4,610)

29,445

45,956

88,177

528,987

Adjusted EBITDA (Non-IFRS)

$

4,545

$

5,063

$

1,564

$

16,924

$

(845)

$

(22,634)

Table 3: Condensed Consolidated Statements of Cash Flow:
(in US$ thousands, unaudited)

Year Ended Dec 31, 2020

Year Ended Dec 31, 2019

Cash provided by (used in) operating activities – continuing operations

16,693

(17,551

)

Cash (used in) operating activities – discontinuing operations

(7,040

)

(10,404

)

Net cash provided by (used in) operating activities

9,653

(27,955

)

Cash (used in) investing activities – continuing operations

(2,578

)

(95,962

)

Cash provided by (used in) investing activities – discontinuing operations

58

(275

)

Net cash (used in) investing activities

(2,520

)

(96,237

)

Cash (used in) provided by financing activities – continuing operations

(2,275

)

29,145

Cash (used in) provided by financing activities – discontinuing operations

(638

)

(633

)

Net cash (used in) provided by financing activities

(2,913

)

28,512

Effect of foreign exchange on cash and cash equivalents

627

1,012

Net change in cash and cash equivalents

4,847

(94,667

)

Cash and cash equivalents, beginning of year

2,579

97,247

Cash and cash equivalents, end of year

$

7,427

$

2,579

Table 4: Condensed Consolidated Statements of Financial Position (Select Items)
(in US$ thousands, unaudited):

($ thousands)

Dec 31, 2020

Dec 31, 2019

Cash and Cash Equivalents

$

7,427

$

2,580

Biological Assets

11,201

8,580

Inventory

52,634

48,169

Total Current Assets

101,889

94,708

Property, Plant & Equipment, Net

66,795

80,576

Total Assets

429,604

545,903

Total Current Liabilities

44,488

50,365

Total Long-Term Liabilities

102,069

111,672

Total Shareholders’ Equity

283,047

383,866

Working Capital

57,401

44,343

The CSE has neither approved nor disapproved the contents of this news release.

Investor Relations Contact:
Taylor Allison
investors@tiltholdings.com

Media Contact:
Ellen Mellody
Ellen@mattio.com
570-209-2947


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Village Farms International, Inc. (VFF) Confirms Majority Ownership Interest in Pure Sunfarms

Village Farms International Confirms Majority Ownership Interest in Pure Sunfarms Village Farms…

Aphria Inc. (APHA) Announces Election of Board of Directors and Executive Appointments and Promotions

Aphria Inc. Announces Election of Board of Directors and Executive Appointments and…

Aphria Inc. (APHA) Doubles Production Capacity After Receiving Cultivation Licence

Aphria Inc. Doubles Production Capacity After Receiving Cultivation Licence for Aphria Diamond…

Marijuana Stocks Newsletter – November 1, 2019

AgraFlora Organics International Inc. (AGRA) (AGFAF) and EuroLife Brands To Deploy Physician-Sanctioned,…